TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Adrian Minson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with chimeric antigen receptor (CAR) T-cell therapies in mantle cell lymphoma (MCL)?

Minson explains why there is a drive to develop new therapies that will lead to more durable remissions in patients with MCL, and how immunotherapeutic agents, such as CAR T-cell therapies, have been beneficial but not without their challenges. Minson then reviews the positive impact of combining ibrutinib with CAR T-cell therapy and examines data on response, survival, and toxicity from the TARMAC trial (NCT04234061), in which this combination was used as a treatment option for MCL.